TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05381467

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: immediate implant placement with The Dual-Zone Therapeutic Concept
Description: After tooth removal, implant placement, bone grafting, and screw retained provisional restoration, the contour of the ridge can change. Using dual zone grafting was claimed to minimize contour change associated with immediate anterior implants. In this technique. The implant should be placed in an optimal 3 dimensional mode . Xenograft, will be used in the gap to graft the bone and tissue zones, . The graft material helps serve as a scaffold to maintain hard- and soft-tissue volume as well as blood clot for initial healing.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Immediate implant placement with the bone shielding concept
Description: After atraumatic tooth extraction using periotomes and luxators , socket curettage and cleaning simultaneously using an irrigation curette will be performed. Sulcular dissection of the attached tissue close to the socket orifice incisal and apically will be done using periotome to create a tunnel via the socket orifice. Dental implant will be placed. complete access of the labial plate of bone where all the regenerative materials will be performed to have the bone sheild delivered. A membrane will be inserted to the labial tunnel and tacked using 2 membrane tacks.
Study: NCT06069960

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: sequential adult left lateral lobe liver transplantation (SALT)
Description: Hemihepatectomy combined with left lateral lobe liver transplantation was performed first, and residual liver resection was performed after the graft grew to a sufficient functional liver volume.
Study: NCT04743388

Intervention type: BIOLOGICAL
Intervention: BNT162b2
Description: Vaccine against SARS-Cov-2 of the Pfizer/BioNTech companies

Intervention type: BIOLOGICAL
Intervention: BNT162b2
Description: Vaccine against SARS-Cov-2 of the Pfizer/BioNTech companies

Intervention type: BIOLOGICAL
Intervention: Other vaccine against SARS-Cov-2
Description: Any other vaccine authorized and administered by the Greek Ministry of Health against SARS-Cov-2

Intervention type: BIOLOGICAL
Intervention: Other vaccine against SARS-Cov-2
Description: Any other vaccine authorized and administered by the Greek Ministry of Health against SARS-Cov-2
Study: NCT05497856

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Integrated neuromuscular inhibition technique
Description: Ischemic compression will be applied for 90 seconds followed by the SCS technique with a reduction in pain of at least 70%. it will be held for 20-30 sec followed by the Muscle energy technique in which the isometric contraction will be held for 7-10 sec and then the stretch will be held for 30 sec. This will be repeated 5 times per session with a 30-second rest interval in between each repetition Session will be held 3 times per week for 2 consecutive weeks

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Myofascial Release
Description: Deep sustained pressure on the trigger points will be applied with thumb in 5-7/10 pain tolerance and maintained for 60 seconds and then will be released in a vertical direction followed by stretch of the rhomboid muscle held for 30 sec. This Sustained manual pressure will be applied for 3 times each followed by a stretch per session with a 30 sec rest interval in between .Session will be held 3 times per week for 2 consecutive weeks.
Study: NCT05834491

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: minimal shoes and foot strengthening and flexibility exercises
Description: Flexible shoes that do not provide support and exercises aimed at increasing the strength of plantar intrinsic and extrinsic foot muscles along with foot flexibility exercises aimed at increasing the range of motion of the foot and ankle

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Supportive Footwear, foot orthotic device and foot flexibility exercises
Description: sturdy supportive shoes fitted with supportive foot orthotic devices and foot flexibility exercises aimed at increasing the range of motion of the foot and ankle
Study: NCT04943562

Intervention type: DIAGNOSTIC_TEST
Intervention: ACT+EEG
Description: Combination of ACT+EEG. This is not an intervention, but rather a combination of devices to be tested regarding its diagnostic validity.

Intervention type: DIAGNOSTIC_TEST
Intervention: ACT+EEG
Description: Combination of ACT+EEG. This is not an intervention, but rather a combination of devices to be tested regarding its diagnostic validity.
Study: NCT05154604

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR-A1921
Description: Treatment group: Subjects will receive an intravenous infusion of SHR-A1921 in a dose escalation until confirmed progression, unaccepted toxicity, or any criterion for withdrawal from the study.
Study: NCT04808271

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Bifidobacterium breve Bif195
Description: 1 capsule daily for 8 weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1 capsule daily for 8 weeks
Study: NCT05281770

Intervention type: DRUG
Intervention: Erenumab
Description: treatment with erenumab as chosen by treating physician

Intervention type: DRUG
Intervention: Fremanezumab
Description: treatment with fremanezumab as chosen by treating physician

Intervention type: DRUG
Intervention: Galcanezumab
Description: treatment with galcanezumab as chosen by treating physician
Study: NCT05942794

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Screening examination
Description: After an initial clinical visit, all three operators will wear the tissue autofluorescence detection device (GOCCLES®), reporting both observations on their operator-module.
Study: NCT06072950

Intervention type: OTHER
Intervention: Usual care
Description: Patients received usual care
Study: NCT06508138

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: pNGVL4a-Sig/E7(detox)/HSP70 plasmid DNA; TA-HPV vaccinia virus
Description: About 1 month before donating blood, donors are required to come to outpatient clinic once a week to receive the following vaccine series:~Week 1: PVX1 (1 of 3): intramuscular injection (IM) of 3mg DNA prime with pNGVL4a-Sig/E7(detox)/HSP70 vaccine Week 2: PVX1 (2 of 3): IM 3mg DNA prime with pNGVL4a-Sig/E7(detox)/HSP70 vaccine Week 3: PVX1 (3 of 3): IM TA-HPV vaccinia boost Pause for 2 weeks Peripheral blood collection and possible bone marrow harvest depending on randomization

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: pNGVL4a-Sig/E7(detox)/HSP70 plasmid DNA; TA-HPV vaccinia virus
Description: About 1 month before donating blood, donors are required to come to outpatient clinic once a week to receive the following vaccine series:~Week 1: PVX1 (1 of 3): intramuscular injection (IM) of 3mg DNA prime with pNGVL4a-Sig/E7(detox)/HSP70 vaccine Week 2: PVX1 (2 of 3): IM 3mg DNA prime with pNGVL4a-Sig/E7(detox)/HSP70 vaccine Week 3: PVX1 (3 of 3): IM TA-HPV vaccinia boost Pause for 2 weeks Peripheral blood collection and possible bone marrow harvest depending on randomization
Study: NCT05147103

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Low-Intensity Focused Ultrasound
Description: LIFU application using various durations, responses of neuromodulation recorded using TMS and EMG.
Study: NCT05455723

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Tracheal Intubation
Description: Inflation-Deflation Technique Versus Magill Forceps Technique for Nasal Intubation by Video-assisted Laryngoscope

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Tracheal Intubation
Description: Inflation-Deflation Technique Versus Magill Forceps Technique for Nasal Intubation by Video-assisted Laryngoscope
Study: NCT04921111

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SCT1000
Description: Recombinant 14 valent human papillomavirus vaccine (6,11,16,18,31,33,35,39,45,51,52,56,58,59) (insect cells)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SCT1000
Description: Recombinant 14 valent human papillomavirus vaccine (6,11,16,18,31,33,35,39,45,51,52,56,58,59) (insect cells)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gardasil®9
Description: Recombinant 9 or 4 valent human papillomavirus vaccine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: aluminium phosphate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: aluminium phosphate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gardasil®
Description: Recombinant 4 valent human papillomavirus vaccine
Study: NCT05159063

Intervention type: DEVICE
Intervention: Ultrasound imaging
Description: Patients scheduled to undergo right heart catheterization (RHC) as their standard of care will be included in the study.~The patient will be positioned supine at 0 degrees with normal restful breathing and patient looking straight up. After the right sternocleidomastoid muscle is identified, internal jugular vein (IJV) will be imaged at the apex of the triangle formed by the sternal and clavicular heads of the muscle. Similarly, the inferior vena cava (IVC) will be imaged at the caudal end of the sternum. The diameters of both the veins will be noted during normal respiration. The patients will then be asked to sniff and collapsibility of the veins will be noted. No pressure will be applied on the neck. The anticipated duration for image acquisition is between 5 to 10 minutes.~The patients will undergo the scheduled RHC within 1 hour as scheduled.
Study: NCT05769166

Intervention type: OTHER
Intervention: thired domain of nordic orofcial test-screen
Description: its a questionnaire which the parent will answer
Study: NCT05332613

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: TRE plus SOC
Description: Participants will undergo time restricted eating (TRE) each day for 12 weeks and will be given lifestyle recommendations with respect to diet (500-1000 kcal) and moderate-intensity exercise (30 minutes).

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: SOC
Description: Participants will be given lifestyle recommendations with respect to diet (500-1000 kcal) and moderate-intensity exercise (30 minutes).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: TRE
Description: Participants will undergo time restricted eating (TRE) each day for 12 weeks plus 4 extra visits with the registered dietician and repeat Fibroscan, InBody composition scan, and MRI-PDFF.
Study: NCT05062070

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TolaSure Topical Gel
Description: TolaSure Topical Gel is applied once-daily for up to 10 weeks to designated Treatment Area and Suction Blister Area.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle Topical Gel
Description: TolaSure Vehicle Gel is applied once-daily for up to 10 weeks to designated Treatment Area and Suction Blister Area.
Study: NCT06216002

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Train of four nerve stimulator
Description: Patient receive nerve stimulation by TOF-scan equipment at recovery room after surgery.
Study: NCT05777772

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: STOP Falls D Educational Intervention
Description: This is one-arm, health-system embedded pragmatic pilot trial
Study: NCT06192459

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Modality physical therapy
Description: Magnetotherapy, low-energy laser, electrotherapy, etc.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Modality physical therapy
Description: Magnetotherapy, low-energy laser, electrotherapy, etc.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Combined therapy:
Description: Muscle strength and joint mobility training, provided twice a week for a duration of three weeks (with assessment on the second session of the third week), totaling six rehabilitation sessions. Additionally, patients are required to engage in daily home-based rehabilitation. During the hospital-based training sessions, a therapist provides guidance and conducts the training. This process encompasses progressive muscle strength training, manual joint mobilization, and active and passive joint movement training to achieve effective rehabilitation outcomes. Each rehabilitation session in the hospital lasts approximately 30 minutes. For home-based training, patients must follow the therapist's instructions and complete 20-30 minutes of home rehabilitation every day. Modality physical therapy are are carry out as usual.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Combined therapy:
Description: Muscle strength and joint mobility training, provided twice a week for a duration of three weeks (with assessment on the second session of the third week), totaling six rehabilitation sessions. Additionally, patients are required to engage in daily home-based rehabilitation. During the hospital-based training sessions, a therapist provides guidance and conducts the training. This process encompasses progressive muscle strength training, manual joint mobilization, and active and passive joint movement training to achieve effective rehabilitation outcomes. Each rehabilitation session in the hospital lasts approximately 30 minutes. For home-based training, patients must follow the therapist's instructions and complete 20-30 minutes of home rehabilitation every day. Modality physical therapy are are carry out as usual.
Study: NCT05799534

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physical Therapy Rehabilitation
Description: Physical Therapy Rehabilitation program to to establish a novel physiotherapeutic plan to determine the effects on post-COVID-19 patients' psychoemotional condition, lung capacity, cardiorespiratory condition, and muscle strength.
Study: NCT04820491

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: X-Ray
Description: Shoulder x-rays as felt necessary for standard of care of diagnosis of shoulder dislocation and reduction

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Ultrasound
Description: Initial evaluation with ultrasound; may also evaluate nearby areas for concern of fracture. Order x- rays after ultrasound as seen fit for other injuries of diagnostic uncertainty.
Study: NCT04669392

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 70% Ethanol Alcohol
Description: Ethanol, also called ethyl alcohol, grain alcohol, or alcohol, a member of a class of organic compounds that are given the general name alcohols.~Ethanol is a commonly used fixative. Fixation of the inner layers of the tissue depends on the ability of the fixative to diffuse into the tissue. Moreover, Ethanol has antibacterial antifungal, and antiviral properties.~70% Ethanol is the safest concentration because the water that has been mixed into the ethanol slows the drying time, creating a longer contact time. Ethanol needs to have a contact time of at least 10 seconds to kill Staphylococcus aureus and Streptococcus pyogenes. At a 10 second drying time.
Study: NCT05242718

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: N-Acetyl-L-cysteine (NAC)
Description: Health Canada Natural Product Number (NPN) 80056946
Study: NCT04954547

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Subsidy Treatment
Description: Participants will be awarded $50 for reaching the PBF goal at the end of 12 weeks. Regardless of goal-attainment, participants will be reimbursed 50% of approved health-improving expenses up to a cap of $300 in the 12 weeks. The subsidy is voluntary and flexible, with no direct intervention from researchers - participants will submit receipts and simply be reimbursed at the end of the experiment (subject to approval from the research team).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cash Treatment
Description: Participants will be awarded $350 for reaching the PBF goal at the end of 12 weeks.
Study: NCT05969873

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pilates exercise
Description: Patients in this group will be treated with pilates exercise and conventional physical therapy as baseline treatment.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Balance training
Description: Patients in this group will be treated with balance training and conventional physical therapy as baseline treatment.
Study: NCT05052060

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Group A
Description: 19 patients will be treated with pelvic tilt exercises

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Group B
Description: 19 patients will be treated with pelvic tilt exercises and facet joint manipulation.
Study: NCT05242718

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Echinacea purpurea
Description: Health Canada Natural Product Number (NPN) 80093896
Study: NCT05275322

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Unified Protocol
Description: The Unified Protocol for transdiagnostic treatment of EDs (hereinafter UP) is a transdiagnostic treatment based on emotional regulation published in 2011 by David H. Barlow et al. (Barlow et al., 2011). It consists of eight treatment modules, with five of them being central (mindfulness, cognitive flexibility, countering emotional behaviors, tolerating physical sensations, and emotional exposure).
Study: NCT05242718

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Curcumin
Description: Health Canada Natural Product Number (NPN) 80043455

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Palmitoylethanolamide
Description: Health Canada Natural Product Number (NPN) 80097472
Study: NCT05722041

Intervention type: PROCEDURE
Intervention: Immediate dental implant placement
Description: Placement of one dental implant immediately after tooth extraction.

Intervention type: PROCEDURE
Intervention: Immediate dental implant placement
Description: Placement of one dental implant immediately after tooth extraction.
Study: NCT03496636

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ovarian tissue transplant
Description: Pieces of previously frozen ovarian cortex will be put in the abdomen laparoscopically, or with mini laparotomy
Study: NCT06415409

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Water
Description: Plain water

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Gatorade
Description: Sport Drink Gatorade

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: BodyArmor
Description: Sport Drink BodyArmor

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: GoodSport
Description: Sport Drink GoodSport
Study: NCT05505357

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Breast surgery omission
Description: For patients who are expected to achieve pathologic complete response after neoadjuvant chemotherapy based on MRI findings, vacuum-assisted biopsy will be performed on the main primary lesion marked with a clip. In case of pCR on vacuum-assisted biopsy specimen, breast surgery will be omitted.
Study: NCT04092790

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Virtual Gate Device (VGD)
Description: A VGD will be applied to one randomly-assigned lower limb. The VGD will be operated constantly (apart from times that the patient is being bathed or undergoing investigations or procedures) providing intermittent stimulations for a maximum of 10 days.
Study: NCT05943145

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Group Dance and Movement Training
Description: Dance movement-based sessions including personalized tasks and imagery, mirroring, and inscription, plus warm-up and cool down practices to ensure physical safety
Study: NCT05663307

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ginkgo diterpene lactone meglumine injection
Description: Intravenous injections of Ginkgo diterpene lactone meglumine injection at a dose of 25 mg (5ml) diluted with 250 ml physiological saline for 14 days plus aspirin at a dose of 100 mg per day for 90 days.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ginkgo diterpene lactone meglumine injection simulation
Description: Intravenous injections of Ginkgo diterpene lactone meglumine injection simulation at a dose of 25 mg (5ml) diluted with 250 ml physiological saline for 14 days plus aspirin at a dose of 100 mg per day for 90 days.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aspirin
Description: plus aspirin at a dose of 100 mg per day for 90 days.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Aspirin
Description: plus aspirin at a dose of 100 mg per day for 90 days.
Study: NCT04803669

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Intrument-assisted soft tissue mobilization technique
Description: This technique; It is applied with the help of a tool made of stainless steel. The instrument is rubbed on the skin at an angle of about 30 degrees, creating a massage-like effect on the soft tissue (2 sessions per week and 5 minutes per session, 8 sessions in total for 4 weeks).

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Treatment
Description: Hotpack, TENS, Ultrasound and Exercise will be applied as conventional treatment methods.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Conventional Treatment
Description: Hotpack, TENS, Ultrasound and Exercise will be applied as conventional treatment methods.
Study: NCT05267132

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Other-Focused Acts of Kindness Intervention with Reflection
Description: Participants engage in positive behaviors by completing acts of kindness for others three times per week. These acts should require effort and be outside of an individual's normal routine. Participants will then reflect on their kind acts after each week.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Other-Focused Acts of Kindness Intervention
Description: Participants engage in positive behaviors by completing acts of kindness for others three times per week. These acts should require effort and be outside of an individual's normal routine.

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Daily Reports
Description: Participants will report their daily activities three times per week. Aside from reporting at the end of the day, no changes should be made to the individual's normal routine.